Catalent (NYSE:CTLT) was upgraded by equities research analysts at First Analysis from a “neutral” rating to an “outperform” rating in a report released on Wednesday, Marketbeat Ratings reports. The firm presently has a $43.00 target price on the stock, down from their prior target price of $47.00. First Analysis’ price objective would suggest a potential upside of 14.61% from the stock’s current price.
A number of other analysts also recently issued reports on CTLT. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. JPMorgan Chase & Co. raised their price objective on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. UBS Group initiated coverage on Catalent in a research report on Tuesday, October 9th. They set a “neutral” rating and a $48.00 price objective for the company. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Catalent presently has a consensus rating of “Buy” and an average target price of $48.11.
Shares of NYSE:CTLT traded down $0.13 during midday trading on Wednesday, reaching $37.52. 303,494 shares of the company’s stock were exchanged, compared to its average volume of 747,139. The company has a current ratio of 2.05, a quick ratio of 1.79 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $5.24 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.15 and a beta of 1.45. Catalent has a fifty-two week low of $34.24 and a fifty-two week high of $47.87.
In other Catalent news, insider John R. Chiminski sold 130,545 shares of Catalent stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $45.32, for a total value of $5,916,299.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders have sold a total of 184,335 shares of company stock valued at $8,161,727 over the last three months. Corporate insiders own 1.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in Catalent in the 2nd quarter valued at about $145,000. Moneta Group Investment Advisors LLC grew its position in Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares in the last quarter. CIBC Asset Management Inc acquired a new position in Catalent in the 3rd quarter valued at about $217,000. Hartford Investment Management Co. acquired a new position in Catalent in the 2nd quarter valued at about $220,000. Finally, Rehmann Capital Advisory Group grew its position in Catalent by 1,895.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares in the last quarter. 92.08% of the stock is owned by institutional investors.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.